In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non–Small Cell Lung Cancer
Authors:
- Ryoji KatoRKRyoji Kato
- Hitendra S. SolankiHSHitendra S. Solanki
- Hilal OzakinciHOHilal Ozakinci
- Bina DesaiBDBina Desai
- Harika GundlapalliHGHarika Gundlapalli
- Yu Chi YangYYYu Chi Yang
- Ida AronchikIAIda Aronchik
- Mallika SinghMSMallika Singh
- Joseph JohnsonJJJoseph Johnson
- Andriy MarusykAMAndriy Marusyk
- Theresa A. BoyleTBTheresa A. Boyle
- Eric B. HauraEHEric B. Haura
- 21 February 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF13
Abstract
Purpose: Therapeutic efficacy of KRASG12C(OFF) inhibitors (KRASG12Ci) in KRASG12C-mutant non–small cell lung cancer (NSCLC) varies widely. The activation status of RAS signaling in tumors with KRASG12C mutation remains unclear, as its ability to cycle between the active GTP-bound and inactive GDP-bound states may influence downstream pathway activation and therapeutic responses. We hypothesized that the interaction between RAS and its downstream effector RAF in tumors may serve as indicators of RAS activity, rendering NSCLC tumors with a high degree of RAS engagement and downstream effects more responsive to KRASG12Ci compared with tumors with lower RAS–RAF interactions. Experimental Design: We developed a method for measuring in situ RAS binding to RAF in cancer samples using proximity ligation assays (PLA) designed to detect panRAS–CRAF interactions. Results: The panRAS–CRAF PLA signal correlated with levels of both RAS-GTP and phosphorylated ERK protein, suggesting that this assay can effectively assess active RAS signaling. We found that elevated panRAS–CRAF PLA signals were associated with increased sensitivity to KRASG12Ci in KRASG12C-mutant NSCLC cell lines, xenograft models, and patient samples. Applying a similar PLA approach to measure the interactions between EGFR and its adapter protein growth factor receptor–bound protein 2 as a surrogate for EGFR activity, we found no relationship between EGFR activity and response to KRASG12Ci in the same samples. Conclusions: Our study highlights the importance of evaluating in situ RAS–RAF interactions as a potential predictive biomarker for identifying patients with NSCLC most likely to benefit from KRASG12Ci. The PLA developed for quantifying these interactions represents a valuable tool for guiding treatment strategies.Keywords
All Related Versions
Funding Information
- National Cancer Institute (UH3CA202970)
This publication has 38 references indexed in Scilit:
- Targeting SHP2 Signaling in Lung CancerJournal of Thoracic Oncology, 2023
- Proximity Ligation Assay for Detecting Protein‐Protein Interactions and Protein Modifications in Cells and Tissues in SituCurrent Protocols in Cell Biology, 2020
- Fully Automated Protein Proximity Assay in Formalin-Fixed, Paraffin-Embedded Tissue Using Caged HaptensBioconjugate Chemistry, 2020
- Differential Effector Engagement by Oncogenic KRASCell Reports, 2018
- EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung AdenocarcinomaJournal of Thoracic Oncology, 2016
- A proposal for validation of antibodiesNature Methods, 2016
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseNature Medicine, 2015
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2015
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialThe Lancet, 2009